JP3193717B2 - チアフィゾベニンのカルバミン酸類縁化合物、医薬品用組成物、ならびにコリンエステラーゼ阻害方法 - Google Patents

チアフィゾベニンのカルバミン酸類縁化合物、医薬品用組成物、ならびにコリンエステラーゼ阻害方法

Info

Publication number
JP3193717B2
JP3193717B2 JP50604593A JP50604593A JP3193717B2 JP 3193717 B2 JP3193717 B2 JP 3193717B2 JP 50604593 A JP50604593 A JP 50604593A JP 50604593 A JP50604593 A JP 50604593A JP 3193717 B2 JP3193717 B2 JP 3193717B2
Authority
JP
Japan
Prior art keywords
group
compound
general formula
effective amount
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50604593A
Other languages
English (en)
Japanese (ja)
Other versions
JPH07505120A (ja
Inventor
ブロッシー、アーノルド
フウ、シャオ−スウ
アイ． ラーペポート、スタンリー
エイチ． グレッグ、ナイジェル
ブロツォストウスカ、マルガルツォータ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JPH07505120A publication Critical patent/JPH07505120A/ja
Application granted granted Critical
Publication of JP3193717B2 publication Critical patent/JP3193717B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
JP50604593A 1991-09-26 1992-08-26 チアフィゾベニンのカルバミン酸類縁化合物、医薬品用組成物、ならびにコリンエステラーゼ阻害方法 Expired - Fee Related JP3193717B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US76576691A 1991-09-26 1991-09-26
US765,766 1991-09-26
US84508192A 1992-03-03 1992-03-03
US845,081 1992-03-03
PCT/US1992/007085 WO1993005779A1 (en) 1991-09-26 1992-08-26 Carbamate analogs of thiaphysovenine, pharmaceutical compositions, and method for inhibiting cholinesterases

Publications (2)

Publication Number Publication Date
JPH07505120A JPH07505120A (ja) 1995-06-08
JP3193717B2 true JP3193717B2 (ja) 2001-07-30

Family

ID=27117648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50604593A Expired - Fee Related JP3193717B2 (ja) 1991-09-26 1992-08-26 チアフィゾベニンのカルバミン酸類縁化合物、医薬品用組成物、ならびにコリンエステラーゼ阻害方法

Country Status (10)

Country Link
US (1) US5378723A (Sortimente)
EP (2) EP0605474B1 (Sortimente)
JP (1) JP3193717B2 (Sortimente)
AT (1) ATE254916T1 (Sortimente)
AU (1) AU667318B2 (Sortimente)
CA (1) CA2119782C (Sortimente)
DE (1) DE69233255T2 (Sortimente)
DK (1) DK0605474T3 (Sortimente)
ES (1) ES2206449T3 (Sortimente)
WO (1) WO1993005779A1 (Sortimente)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69832688T2 (de) * 1997-07-09 2006-09-07 Axonyx Hochselektive butyrylcholinesterase inhibitoren zur behandlung und zur diagnose von demenz und alzheimers krankheit
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
EP1349858B1 (en) 2000-11-02 2008-08-27 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20070129350A1 (en) * 2004-01-30 2007-06-07 Axonyx, Inc. Methods for treatment of diabetes
CN102379684B (zh) 2005-04-28 2014-11-19 普罗透斯数字保健公司 药物信息系统
CN101594878A (zh) 2006-09-18 2009-12-02 雷普特药品公司 通过给予受体相关蛋白（rap）-缀合物对肝病症的治疗
NZ616673A (en) 2009-02-20 2014-08-29 To Bbb Holding B V Glutathione-based drug delivery system
CN110075069A (zh) 2009-05-06 2019-08-02 实验室护肤股份有限公司 包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其应用
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
KR101667215B1 (ko) 2014-10-21 2016-10-18 한밭대학교 산학협력단 신규한 트립타민 컨쥬게이트 화합물 및 그의 용도
KR102233120B1 (ko) 2018-12-18 2021-03-29 한밭대학교 산학협력단 신규한 파에오놀-트립타민 화합물 및 그의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133930A (en) * 1961-08-15 1964-05-19 Ciba Geigy Corp Ester and amide derivatives of thieno-[3, 2-b] indole 3-carboxylic acids
US4900748A (en) * 1988-03-04 1990-02-13 The United States Of America As Represented By The Department Of Health And Human Services Carbamates related to (-)-physostigmine as cholinergic agents

Also Published As

Publication number Publication date
AU667318B2 (en) 1996-03-21
EP0605474B1 (en) 2003-11-26
ATE254916T1 (de) 2003-12-15
EP0605474A4 (Sortimente) 1994-08-03
DE69233255T2 (de) 2004-05-27
ES2206449T3 (es) 2004-05-16
EP1251131A2 (en) 2002-10-23
CA2119782C (en) 2005-08-23
EP1251131A3 (en) 2002-10-30
EP0605474A1 (en) 1994-07-13
CA2119782A1 (en) 1993-04-01
US5378723A (en) 1995-01-03
DE69233255D1 (de) 2004-01-08
JPH07505120A (ja) 1995-06-08
DK0605474T3 (da) 2004-02-23
WO1993005779A1 (en) 1993-04-01
AU2504292A (en) 1993-04-27

Similar Documents

Publication Publication Date Title
US6268358B1 (en) Compounds for the treatment of Alzheimer's disease
JP3708957B2 (ja) （−）−エゼロリン、（−）−ｎ１−ノルエゼロリンおよび（−）−ｎ１−ベンジルノルエゼロリンの置換フェンゼリンおよびフェニルカルバミン酸塩：特異的アセチルコリンエステラーゼ阻害薬としての使用
US4900748A (en) Carbamates related to (-)-physostigmine as cholinergic agents
JP3193717B2 (ja) チアフィゾベニンのカルバミン酸類縁化合物、医薬品用組成物、ならびにコリンエステラーゼ阻害方法
EP0429685A1 (en) Oxoindole derivative
KR100225927B1 (ko) 콜린에스테라제 저해제로서의 제네세린 유도체
CZ63799A3 (cs) Spirocyklické metalloproteázové inhibitory
EP0509400B1 (en) 1-(Pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles, intermediates and a process for their preparation, and their use as medicaments
JP2665422B2 (ja) 置換された１，２，３，４−テトラヒドロシクロペント〔ｂ〕インドール、１，２，３，３ａ，４，８ａ−ヘキサヒドロシクロペント〔ｂ〕インドールおよび関連化合物
IL99581A (en) Substituted-4-amino-3-pyridinols, a process for their preparation and pharmaceutical compositions containing them
DE69329084T2 (de) Benzoxazepin-Derivate als Cholinesterase-Inhibitoren
EP0326106A2 (en) Alkylene diamines
NZ223485A (en) 9-amino-1,4-ethano-1,2,3,4-tetrahydroacridine derivatives and their preparation
US5026897A (en) Carbaphens: aprophen analogs that are binary antidotes for organophosphate poisoning
SI9300331A (sl) Azaciklicni in azabiciklicni alkiliden hidroksilamini
AU609872B2 (en) N-(substituted alkylidene)fused-bicycloalkylidene and heteroalkylidene quinolinamines, a process for their preparation and their use as medicaments
EP0440145A1 (en) Hexahydropyrrolo[2,3-b]indole carbamates,-ureas,-amides and related compounds, a process for their preparation and their use as medicaments
CA1140930A (en) Heterocyclic spiro-linked amidines, their stereoisomers and optical isomers, processes for their preparation and medicaments containing these compounds
DE69916663T2 (de) Tetrahydroisochinolinalkanol-derivate und diese enthaltende pharmazeutische zubereitungen
EP0285018A2 (en) Substituted 9-Amino-Spiro [cycloalkyl[b]quinoline-2,1'cycloalkanes], a process and intermediates for their preparation and their use as medicaments
NO120581B (Sortimente)
KR100590827B1 (ko) 테트라히드로이소퀴놀린알칸올 유도체 및 이를 함유하는약학적 조성물
SK162295A3 (en) N-substituted azaheterocyclic carboxylic acids and esters thereof
SK2996A3 (en) Methanoanthracenes substituted by piperidinyl group, preparation method thereof and their use as d1/d2-dopamine-antagonists and 5ht2-serotonin-antagonists
HU211639A9 (hu) Cerebrális működést serkentő biciklolaktám származékok Az átmeneti oltalom az 1-4. igénypontokra vonatkozik.

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090525

Year of fee payment: 8

LAPS Cancellation because of no payment of annual fees